The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study

Abdelhady, Ayman; Khader, Said; Sinnuqrut, Samy; Albow, Abdullah

doi:10.1007/s40261-015-0370-y

Cited by 3 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of cough leading to discontinuation of treatment was 1/10 (0.1%). In other studies, the incidence of patients experiencing dry cough while using perindopril/amlodipine FDC was reported as 1/ 13 in the study by Liakos et al (2017), 4/25 in Vlachopoulos et al (2016, 1/7 in Nagy (2013), 5% in Abdelhady et al (2016), and 0.2% in Forster and Dézsi (2016).…”

Section: Safetymentioning

confidence: 79%

“…Most studies examined the therapeutic efficacy of perindopril/amlodipine FDC at doses of 5/5, 5/10, 10/5, and 10/10 mg in untreated or uncontrolled hypertensive patients with previous treatment. Table 1 shows the effectiveness in reducing BP and increasing the BP control rates in the total hypertensive population of the studies ( Nagy, 2013 ; Manolis et al, 2015 ; Abdelhady et al, 2016 ; Forster and Dézsi, 2016 ; Vlachopoulos et al, 2016 ; Liakos et al, 2017 ; Fleig et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

“…When comparing hypertensive patients with and without diabetes, the rate of BP control achieved was 87% of patients, with no significant difference between groups (86% and 88%, p = 0.499), and BP decreased by 31/18 mmHg ( p < 0.001) after 3 months of using perindopril/amlodipine FDC ( Ahmed et al, 2016 ). The mean proportion of patients with controlled BP was 93.3% at week 12, of which the proportion of patients without diabetes was 96.4% and of patients with diabetes was 89.0% ( Abdelhady et al, 2016 ).…”

Section: Resultsmentioning

confidence: 99%

“…The reported incidence of ankle edema ranges from 0.6% to 16% ( Bansal et al, 2014 ; Abdelhady et al, 2016 ; Forster and Dézsi, 2016 ). Hatalova et al (2016) showed that the risk associated with ankle edema, compared with previous treatment with ACEIs and/or CCBs, was −37.5% in the first month ( p < 0.001) and −57.2% in the third month ( p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Dat,

Tu,

Thu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Uncontrolled blood pressure is a major risk factor for cardiovascular diseases. Fixed-dose combination (FDC) therapy offers a promising approach to addressing this challenge by providing a convenient single-tablet solution that enhances the effectiveness of blood pressure control. In our systematic review, we assess the effectiveness of perindopril/amlodipine FDC in managing blood pressure.Methods: We conducted a comprehensive search across four primary electronic databases, namely, PubMed, Virtual Health Library (VHL), Global Health Library (GHL), and Google Scholar, as of 8 February 2022. Additionally, we performed a manual search to find relevant articles. The quality of the selected articles was evaluated using the Study Quality Assessment Tools (SQAT) checklist from the National Institute of Health and the ROB2 tool from Cochrane.Results: Our systematic review included 17 eligible articles. The findings show that the use of perindopril/amlodipine FDC significantly lowers blood pressure and enhances the quality of blood pressure control. Compared to the comparison group, the perindopril/amlodipine combination tablet resulted in a higher rate of blood pressure response and normalization. Importantly, perindopril/amlodipine FDC contributes to improved patient adherence with minimal side effects. However, studies conducted to date have not provided assessments of the cost-effectiveness of perindopril/amlodipine FDC.Conclusion: In summary, our analysis confirms the effectiveness of perindopril/amlodipine FDC in lowering blood pressure, with combination therapy outperforming monotherapy and placebo. Although mild adverse reactions were observed in a small subset of participants, cost-effectiveness assessments for this treatment remain lacking in the literature.

show abstract

Section: Safetymentioning

confidence: 79%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Dat,

Tu,

Thu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…There are new laboratory data on the effects of telmisartan on oxidative stress, myocardial ischemia, and immune response. Authors have observed an increase in catalase and superoxide dismutase expression levels under telmisartan treatment, with a decrease in injury and oxidative biomarker levels, and have concluded that telmisartan reduced 18 .…”

Section: Discussionmentioning

confidence: 99%

Clinical and functional predictors that cause a decrease of indicators of morning blood pressure profile in antihypertensive telmisartan-based therapy

Распутіна

Didenkо

2020

Biomed. Res. Ther.

View full text Add to dashboard Cite

Background: Blood pressure (BP) monitoring is an important aspect in the treatment of arterial hypertension (AH), namely the morning BP increase which is associated with an increased risk of cardiovascular and cerebrovascular incidents as well as sudden death. The study herein revealed clinical and functional predictors which decrease the morning BP rise in the case of optimal antihypertensive therapy with telmisartan, based on results of daily blood pressure monitoring (DBPM). Methods: A single-center open-label study in parallel groups was conducted. The study included 50 patients with AH who had previously received antihypertensive therapy but did not achieve a reduction in BP according to DBPM. Telmisartan (40 - 80 mg per day) was added to the treatment regimen of all patients. All patients underwent a general clinical examination, measurement of glucose and creatinine levels, assessment of lipid profile, ECG recording in 12 leads, echocardiography (EchoCG), and DBPM before treatment and after 12 weeks of treatment. Statistical data analyses were performed. Results: Twelve-week antihypertensive telmisartan-based therapy led to a decrease in mean systolic blood pressure (SBP) from 134.3 ± 5.0 to 126.2 ± 4.3 mm Hg (p = 0.008), and a decrease in mean diastolic blood pressure (DBP) from 79.8 ± 1.5 to 73.0 ± 1.4 mm Hg (p < 0.001). There was a decrease in the index of variability of DBP from 22.4 ± 2.8 to 16 ± 2.4 mm Hg (p < 0.001), and a decrease in the daily index of SBP from 15.7 ± 4.7 to 13.1 ± 4.7 mm Hg (p = 0.014). In the study, a connection was found between the decrease of the average morning index and the following indicators: presence of left ventricular (LV) hypertrophy on ECG, final diastolic size of the LV over 6.0 cm, LV ejection fraction below 52.3%, total cholesterol level over 5.5 mmol/L, LDL level greater than 3.3 mmol/L, and triglyceride level greater than 2.0 mmol/L. Conclusion: These values could be used as predictors of a decrease in the morning index during 12-week telmisartan therapy.

show abstract

Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation

Elliott

Bistrika

2017

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Controlling blood pressure is a global health priority; single-pill antihypertensive combinations may improve adherence, persistence, and outcomes. Areas covered: A novel combination of perindopril arginine and amlodipine besylate was recently approved. A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension. Dose-dependent hyperkalemia, impairment of renal function (especially in renovascular hypertension), angioedema, and teratogenicity were derived from experience with other ACE-inhibitors. Expert opinion: Substantial clinical trial experience with amlodipine or perindopril suggests that these two agents effectively lower blood pressure, and can reduce the risk of major adverse cardiovascular events, as in the Anglo-Scandinavian Cardiac Outcomes Trial. The incidence of adverse effects reported in clinical trials is lower than expected, likely due to exclusion of subjects previously exposed to its components; the nature of open-label, uncontrolled observational studies; and difficulty in recognizing and measuring cough and pedal edema. This new formulation of perindopril arginine protects its ethyl ester, without requiring physical separation from amlodipine in a single tablet, and is less hygroscopic than perindopril erbumine. These and other attributes may make this combination an attractive addition to the antihypertensive armamentarium.

show abstract

The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study

Abstract: We found that a fixed combination of perindopril/amlodipine is effective in controlling BP in patients with essential hypertension, with older age, male gender, and diabetes mellitus being independent risk factors for less BP control.

Cited by 3 publications

References 33 publications

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

Clinical and functional predictors that cause a decrease of indicators of morning blood pressure profile in antihypertensive telmisartan-based therapy

Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation

Contact Info

Product

Resources

About